Idenix CEO on Hep C Drug Study

Insight on the FDA clearing Idenix to resume study of its advanced experimental hepatitis C drug, with Ronald Renaud, Idenix president/CEO.

CNBC | February 14, 2012

Tags:. .hep. .renaud. .ronald. .resume. .hepatitis